A barbiturate once commonly used to treat anxiety may play a role in controlling the spread of colon cancer, say researchers from The University of Texas M. D. Anderson Cancer Center.Their experimental model
This week's editorial calls on GlaxoSmithKline (GSK) to make all its research on paroxetine (Seroxat/Paxil) publicly available. This follows the filing of last week's law suit by the state of New York against GSK: the stat
Health Canada is advising Canadians that Selective Serotonin Re-uptake Inhibitors (SSRIs) and other newer anti-depressants, now carry stronger warnings. These new warnings indicate that patients of all ages taking these drugs may experience behavioural and
New results from TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) demonstrated that Enbrel? (etanercept) therapy allowed significantly more rheumatoid arthritis (RA) patients to achieve clinical remission at two years compare
Wyeth Pharmaceuticals, the pharmaceutical division of Wyeth, announced today important new study findings for RAPAMUNE? (sirolimus). Kidney histology and function three years after transplantation are better in kid
GW Pharmaceuticals plc announces positive preliminary results in a Phase II clinical trial in patients with pain caused by Rheumatoid Arthritis. The multi centre double blind, randomised, parallel grou
Companies developing new drugs for the global market must deal with the rising costs of the R&D process - and outsourcing may well be the best route. That's the verdict of Dr Faiz Kermani, a specialist in outsourcing and research development for the
Xenova Group plc has announced the presentation of results of two dose escalation Phase II studies of TA-CD, a vaccine being developed for the treatment of cocaine addiction, at the College on Problems of Drug Depende
Findings reported in a study published today in the Archives of Internal Medicine found that over half of patients within a predominantly retiree population taking COX-2 anti-inflammatory drugs on a long-term basis were also taking aspirin therapy f
Biovail Corporation has announced that the Food and Drug Administration (FDA) has accepted for review (effective date June 13, 2004) Biovail's submission of a New Drug Application (NDA) for a novel dosa
Velac is an investigational new drug that combines clindamycin 1% and tretinoin 0.025% in a gel formulation as a potential new topical treatment for acne. In March, Connetics announced positive results from its Phase III clinical trials with Velac versus clindamycin gel and tretinoin gel for the treatment of acne.
The topical prescription acne category is one of the largest segments in the U.S. dermatology market, and is estimated to exceed $1.2 billion annually. Approximately 17 million people in the U.S. have acne resulting in approximately 5.5 million office visits per year.
http://www.connetics.com/